Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.20+0.07 (+0.77%)
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Syndax Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Syndax Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$177.36M. For fiscal 2025 it was -$322.98M. The highest annual figure on record is $29.13M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$322.98M | – |
| FY2024 | Dec 31, 2024 | -$274.90M | – |
| FY2023 | Dec 31, 2023 | -$160.60M | – |
| FY2022 | Dec 31, 2022 | -$133.68M | -558.9% |
| FY2021 | Dec 31, 2021 | $29.13M | – |
| FY2020 | Dec 31, 2020 | -$71.26M | – |
| FY2019 | Dec 31, 2019 | -$50.61M | – |
| FY2018 | Dec 31, 2018 | -$68.53M | – |
| FY2017 | Dec 31, 2017 | -$47.37M | – |
| FY2016 | Dec 31, 2016 | -$35.16M | – |
| FY2015 | Dec 31, 2015 | -$2.43M | – |
| FY2014 | Dec 31, 2014 | -$14.39M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.25M | – |
| Q2 FY2026 | Jun 30, 2026 | -$30.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$50.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$70.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$87.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$95.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$57.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$62.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$83.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.89M | -122.7% |
| Q3 FY2022 | Sep 30, 2022 | -$28.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$40.31M | – |
| Q1 FY2022 | Mar 31, 2022 | -$41.93M | – |
| Q4 FY2021 | Dec 31, 2021 | $100.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.53M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.47M | – |
| Q2 FY2018 | Jun 30, 2018 | -$15.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.87M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.80M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.67M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.42M | – |
See a number that looks wrong?